Navigation Links
Australian Biotech Ceridia Pty Ltd Completes Successful Human Clinical Trial
Date:7/26/2011

ADELAIDE, Australia, July 26, 2011 /PRNewswire/ -- Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.  CER006 was designed to be a model formulation to establish safety and tolerability of Ceridia's LipoCeramic reformulation technology but also to attain pharmacokinetic information in humans.

Trial demonstrates that the technology is safe and well tolerated. Study also suggests fast and improved delivery of ibuprofen when comparing with branded market leader.

Based on the safety and pharmacokinetics data from this 4-arm blinded study, Ceridia plans to commence a number of bio-equivalence and bioavailability trials which will include anti-inflammatory, anti-infective and oncology drugs.

"We are very pleased to demonstrate that Ceridia's LipoCeramic platform technology is safe and well tolerated in humans.  It is a clinical validation of more than 10 years of research and development," said Dr Gregor Rozenberg, Ph.D., CEO, Ceridia. "We are now poised to initiate a number of Phase 2 studies with the aim of reformulating and improving the clinical profiles of several therapeutic drugs.  Commercialisation can now be accelerated."

Ceridia Pty Ltd is supported by ITEK, the intellectual property commercialisation arm of UniSA and has entered into collaborations with Pharma and Biotech using its innovative reformulation technology to improve existing and novel drugs. The company is seeking additional investment and partnerships.

Reformulating approved drugs enables reprofiling or repurposing of therapeutic agents. This in turn provides new commercial opportunities in an abbreviated regulatory environment. This reduces development times significantly and produces better drugs quicker and cheaper.

Ceridia

Ceridia is a privately owned spin-out company of the University of South Australia.  Ceridia is commercializing a novel method of reformulating oil-soluble compounds.  A silica-lipid nano-encapsulation platform technology has been developed and protected by patents worldwide.  This technology enables the pharmaceutical and biotechnology industry to improve efficacy, bio-availability and stability of drugs and help reduce their time to market.  The technology is clinically proven to be completely safe, uses no synthetic, toxic or corrosive solvents. The manufacturing process is straightforward and can be quickly transferred into most API manufacturing sites and requires no additional capital expenditure.  Human clinical trials indicate improved clinical profile and quicker drug uptake.

Contact:
Gregor Rozenberg, CEO
Email: gregor@ceridia.com.au
Website: www.ceridia.com.au


'/>"/>
SOURCE Ceridia Pty Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
2. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
3. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. New Australian Technology: Detecting Breast Cancer With Hair
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Top 5 Ways to Get Insider Track on Healthcare, Pharma & Biotech Discoveries & Latest News
8. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
9. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
10. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
11. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... March 28, 2017 The global ... USD 8.0 billion by 2025, according to a new ... of infectious diseases and cancer is expected to upsurge ... diagnosis over the coming years. In addition, higher number ... and allogenic stem cell therapy, due to adverse effects ...
(Date:3/27/2017)... Summary This report provides all the ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... WI (PRWEB) , ... March 27, 2017 , ... ... new patients for custom smile makeovers without requiring a referral. Trimble ... orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Drs. Justin ... Awareness Week by teaching their patients about the key role this treatment plays in ... from an experienced endodontist. To better serve those who need a root canal in ...
(Date:3/27/2017)... Arlington, VA (PRWEB) , ... March 27, 2017 ... ... version 3.0 was transitioned to the OSEHRA popHealth Community in 2014. ... Steering Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
Breaking Medicine News(10 mins):